Cancer‑Associated Thrombosis in Patients with Unprovoked VTE and Hepatic Infarct

Epidemiology & Risk Assessment

Approximately 10 % of patients with unprovoked venous thromboembolism develop cancer‑associated thrombosis, and these patients experience a 4‑ to 13‑fold higher incidence of recurrent thrombotic events. (National Comprehensive Cancer Network guideline) 1

A complete blood count revealing platelet count ≥ 350 × 10⁹/L, hemoglobin < 10 g/dL, or leukocyte count > 11 × 10⁹/L is linked to an increased likelihood of occult malignancy. (NCCN guideline) 1
A comprehensive metabolic panel—including liver and renal function tests—is essential both for cancer screening and for safe anticoagulation management. (NCCN guideline) 1
Coagulation studies (PT/INR, aPTT, fibrinogen) should be obtained to verify current anticoagulation status and to detect consumptive coagulopathy. (NCCN guideline) 1

Perform a contrast‑enhanced CT of the chest, abdomen, and pelvis with priority given to detecting pancreatic, gastric, lung, and gynecologic malignancies—the cancers most strongly associated with thrombosis. (Blood 2013 study) 2

The NCCN guideline recommends low‑molecular‑weight heparin (LMWH)—e.g., dalteparin 200 U/kg subcutaneously daily or enoxaparin 1 mg/kg subcutaneously every 12 h—as superior to warfarin for treating cancer‑associated thrombosis. (NCCN guideline; Blood 2013) [1][2]
Development of new thrombosis while on therapeutic warfarin (presumed therapeutic INR) constitutes treatment failure and strongly suggests either cancer‑associated thrombosis or antiphospholipid syndrome; both conditions typically respond better to LMWH. (NCCN guideline; Blood 2013) [1][2]

When an underlying malignancy is identified, indefinite anticoagulation is advised because of the high‑risk profile (bilateral DVT, hepatic infarct, prior stroke). (NCCN guideline) 1

CT imaging should be reviewed for portal or hepatic vein thrombosis, which may indicate Budd‑Chiari syndrome or portal vein thrombosis—conditions frequently associated with myeloproliferative neoplasms. (NCCN guideline) 1

Do not delay cancer screening; the combination of bilateral DVT and an atypical thrombotic site (hepatic infarct) while on anticoagulation is a red‑flag for occult malignancy. (NCCN guideline) 1
Do not continue warfarin without reassessment; ongoing thrombosis on warfarin suggests subtherapeutic INR, cancer‑associated thrombosis, or antiphospholipid syndrome and warrants a change in anticoagulant strategy. (NCCN guideline; Blood 2013) [1][2]

Arrange an urgent hematology/oncology consultation within 1–2 weeks to coordinate comprehensive cancer evaluation and anticoagulation management. (NCCN guideline) 1

The American College of Oncology recommends a complete physical examination, blood tests, chest radiography, and urological or gynecological evaluation in patients with idiopathic deep vein thrombosis (DVT) 3
The National Comprehensive Cancer Network suggests that all patients with DVT should receive a complete history and physical examination, complete blood count with platelet count, prothrombin time, partial thromboplastin time, and liver and kidney function tests 4, 5

Patients with idiopathic DVT have a higher risk of occult cancer, and the following factors identify patients with a higher risk of cancer-associated thrombosis: stomach, pancreas, lung, lymphoma, gynecological, and genitourinary cancers 3, 5, 6
Laboratory parameters such as platelet count ≥350 × 10⁹/L, hemoglobin <10 g/dL, leukocytes >11 × 10⁹/L, and body mass index ≥35 kg/m² are also associated with a higher risk of cancer 6

The American College of Oncology recommends that diagnostic testing should be directed, not exhaustive, and that costly studies such as computed tomography, endoscopy, or tumor markers should only be ordered when there is a strong clinical suspicion of occult cancer 3
The National Comprehensive Cancer Network suggests that the evaluation of patients with DVT should be based on clinical findings during the physical examination and initial evaluation 4, 5

Patients with metastatic or advanced cancer have a 4- to 13-fold higher incidence of DVT compared to those with localized disease 3
The use of bevacizumab increases the risk of developing DVT 3, 6